

Supplemental table 1A. Corpus pathology scores at 16 WPI

Treatment	Count	Inflammation	Epithelial defects	Oxyntic atrophy	Foveolar hyperplasia	Intestinal metaplasia	Dysplasia	GHAI
Uninfected female	5	1.0 ± 0.0	0.3 ± 0.4	1.0 ± 0.0	2.6 ± 0.2	0.0 ± 0.0	0.2 ± 0.3	5.1 ± 0.5
Uninfected male	5	0.8 ± 0.3	0.9 ± 0.7	1.4 ± 0.2	2.0 ± 0.0	0.7 ± 0.7	0.7 ± 0.7	6.5 ± 1.8
Infected female	5	1.7 ± 0.3	0.7 ± 0.3	2.4 ± 0.4	3.5 ± 0.0	2.1 ± 0.2	1.0 ± 0.4	11.4 ± 1.2
Infected male	5	1.8 ± 0.3	1.7 ± 0.3	2.4 ± 0.4	3.2 ± 0.3	1.9 ± 0.7	1.2 ± 0.4	12.2 ± 1.9

Supplemental table 1B. Corpus pathology scores at 28 WPI

Treatment	Count	Inflammation	Epithelial defects	Oxyntic atrophy	Foveolar hyperplasia	Intestinal metaplasia	Dysplasia	GHAI
Uninfected untreated male	12	0.8 ± 0.3	1.2 ± 0.7	1.2 ± 0.5	1.4 ± 0.5	0.3 ± 0.3	0.9 ± 0.4	5.8 ± 1.8
Uninfected estradiol male	10	0.6 ± 0.4	0.6 ± 0.5	0.5 ± 0.2	1.0 ± 0.5	0.1 ± 0.2	0.3 ± 0.3	3.0 ± 1.1
Uninfected Tamoxifen male	6	0.8 ± 0.3	0.9 ± 0.2	1.1 ± 0.6	0.9 ± 0.2	0.3 ± 0.3	0.6 ± 0.2	4.5 ± 0.9
Uninfected E2 + Tam male	7	0.4 ± 0.2	0.3 ± 0.3	0.3 ± 0.3	0.8 ± 0.5	0.0 ± 0.0	0.0 ± 0.0	1.8 ± 1.0
Infected untreated male	10	2.5 ± 0.0	2.8 ± 0.3	2.5 ± 0.3	3.5 ± 0.4	2.9 ± 0.2	2.9 ± 0.5	17.1 ± 1.2
Infected estradiol male	9	1.9 ± 0.6	1.4 ± 0.9	2.6 ± 0.5	2.7 ± 0.7	2.4 ± 0.8	1.6 ± 0.7	12.6 ± 3.7
Infected Tamoxifen male	7	1.9 ± 0.3	2.4 ± 0.5	2.9 ± 0.2	1.9 ± 0.5	2.8 ± 0.4	1.6 ± 0.2	13.6 ± 0.7
Infected E2 + Tam male	4	2.1 ± 0.3	2.5 ± 0.7	2.3 ± 0.3	2.5 ± 0.4	2.4 ± 0.3	2.1 ± 0.5	13.9 ± 1.9
Uninfected untreated female	9	0.8 ± 0.4	0.3 ± 0.4	1.3 ± 0.3	1.8 ± 0.7	0.0 ± 0.0	0.4 ± 0.2	4.6 ± 1.5
Uninfected Tamoxifen female	1	0.5	0.0	0.5	1.0	0.0	0.0	2.0
Infected untreated female	10	1.3 ± 0.3	0.9 ± 0.5	2.8 ± 0.4	2.3 ± 0.5	2.6 ± 0.6	1.6 ± 0.5	11.4 ± 1.9
Infected Tamoxifen female	9	1.6 ± 0.3	1.2 ± 0.8	2.9 ± 0.2	2.1 ± 0.3	2.8 ± 0.4	1.7 ± 0.4	12.2 ± 1.2

Supplemental table 1C. Antrum pathology scores at 16 WPI

Treatment	Count	Inflammation	Epithelial defects	Hyperplasia	Dysplasia	GHA1
Uninfected female	5	0.0 ± 0.0	0.0 ± 0.0	0.7 ± 0.8	0.3 ± 0.3	1.0 ± 0.9
Uninfected male	5	0.1 ± 0.2	0.0 ± 0.0	0.6 ± 0.2	0.3 ± 0.3	1.0 ± 0.5
Infected female	5	0.4 ± 0.2	0.3 ± 0.3	1.3 ± 0.7	0.8 ± 0.6	2.8 ± 1.4
Infected male	5	0.3 ± 0.3	0.2 ± 0.3	1.1 ± 0.5	0.5 ± 0.4	2.1 ± 1.1

Supplemental table 1D. Antrum pathology scores at 28 WPI

Treatment	Count	Inflammation	Epithelial defects	Hyperplasia	Dysplasia	GHA1
Uninfected untreated male	12	0.1 ± 0.2	0.0 ± 0.0	0.8 ± 0.3	0.6 ± 0.2	1.4 ± 0.4
Uninfected estradiol male	10	0.0 ± 0.0	0.0 ± 0.0	0.7 ± 0.2	0.5 ± 0.0	1.2 ± 0.2
Uninfected Tamoxifen male	6	0.0 ± 0.0	0.0 ± 0.0	0.7 ± 0.3	0.4 ± 0.2	1.1 ± 0.4
Uninfected E2 + Tam male	7	0.0 ± 0.0	0.0 ± 0.0	0.6 ± 0.2	0.4 ± 0.2	0.9 ± 0.3
Infected untreated male	10	0.7 ± 0.2	0.0 ± 0.0	1.1 ± 0.6	0.8 ± 0.3	2.5 ± 1.1
Infected estradiol male	9	0.0 ± 0.0	0.0 ± 0.0	0.3 ± 0.3	0.1 ± 0.2	0.4 ± 0.2
Infected Tamoxifen male	7	0.0 ± 0.0	0.0 ± 0.0	0.5 ± 0.3	0.1 ± 0.2	0.6 ± 0.4
Infected E2 + Tam male	4	0.1 ± 0.3	0.0 ± 0.0	0.6 ± 0.3	0.4 ± 0.3	1.1 ± 0.5
Uninfected untreated female	9	0.1 ± 0.2	0.0 ± 0.0	0.4 ± 0.2	0.4 ± 0.2	0.9 ± 0.2
Uninfected Tamoxifen female	1	0.0	0.0	0.5	0.5	1.0
Infected untreated female	10	0.4 ± 0.3	0.0 ± 0.0	0.8 ± 0.4	0.3 ± 0.3	1.5 ± 0.7
Infected Tamoxifen female	9	0.3 ± 0.3	0.0 ± 0.0	0.6 ± 0.4	0.2 ± 0.3	1.2 ± 0.6